A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
Completed
Ferring Pharmaceuticals
Phase 3
2007-03-01
Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486
CS21A study. The study continued until all non-discontinued participants had received
treatment for at least 5 years.
Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer
Completed
Ferring Pharmaceuticals
Phase 3
2008-12-01
The purpose of this uncontrolled, multi-center, open-label trial was to investigate the
feasibility of using degarelix as intermittent androgen deprivation (IAD) therapy in the
treatment of prostate cancer.
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Completed
Ferring Pharmaceuticals
Phase 3
2009-04-01
The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in
terms of reducing the size of the prostate volume in prostate cancer patients who were
scheduled to undergo subsequent radiotherapy for treatment of their prostate cancer. Prior to
receiving radiotherapy, it is recommended that patients with intermediate to high risk
prostate cancer are pre-treated with hormone therapy (so-called neoadjuvant therapy) which is
known to reduce the size of the prostate and thereby decrease the required radiation field
and enable a more safe and effective treatment. In this trial, participants were randomly
selected (like flipping a coin) to receive either degarelix given alone or a standard hormone
therapy (combination of goserelin and bicalutamide. The treatment was given for three months
and the prostate size was measured by ultra sound at the beginning and at the end of the
trial. The participants were required to come to the clinic for 5 or 6 visits during the
three months.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
